Industry-leading data creation and analysis are needed in the healthcare system to provide quick services. Pharmaceutical, diagnostic, and technology partners rely on Decode Health to offer precise and trustworthy insights from vast, complex datasets, with ROI evaluated in weeks rather than years. In order to uncover discoveries with data, Decode Health, a leader in healthcare artificial intelligence, enables an ecosystem of top diagnostic and pharmaceutical firms. The generation of genetic data, RNA diagnostics, and population health analytics are all ongoing endeavors. The group in charge of Decode has developed a framework over the course of a decade by combining many cutting-edge machine learning techniques. In order to spur innovation and promote precision medicine, the business uses a flexible, scalable strategy that blends clinical data with SDoH and non-clinical data. The data assets, goods, and services provided by Decode enhance patient outcomes, cut costs, and advance health equity.

Decode is conducting ground-breaking research in RNA genetics and sophisticated population health analytics that speeds up innovation and time to market for firms developing innovative diagnostic, pharmacological, and technological products and services. Decode Health has refined its methodology over time to better organise data, highlight illness trends, and unearth practical insights that speed up time to value for Decode’s ecosystem partners. The Decode team develops cutting-edge clinical decision support systems and molecular diagnostics that foretell health outcomes by analysing genetic, clinical, and social determinants of health (SDoH) data using machine learning. Examples of Decode’s work include developing prediction models to categorise older cancer patients into personas to assess treatment tolerance and teaming up with Quest Diagnostics to find novel biomarkers to enhance the capacity to recognise, forecast, and treat disease. The predictive capacities of Decode enhance results, reduce expenses, and advance health equity. Decode is developing predictive models in collaboration with a global pharmaceutical business to identify distinct cancer patient personalities and comprehend chemoresistance. Future clinical studies will benefit from these insights, which will also provide clinical decision support tools that will help choose the best course of action.

The greatest risk demographics can be identified using Decode’s SDoH-driven algorithms in collaboration with governmental organizations. With the use of these findings, organisations may direct resources for testing and treatment toward the regions and populations with the highest risk while enhancing health equity. In order to help local agencies control the spread of the COVID epidemic, they developed algorithms to forecast results and pinpoint treatment-related obstacles.

In order to further medicine and diagnostics research and development in the expanding disciplines of metabolic illness and autoimmune neurology, Decode Health has announced a new phase of its relationship with Quest Diagnostics, the world’s top supplier of diagnostic information services. Based on their respective next-generation sequencing, analytics, and clinical experience, the two parties built RNA (transcriptome) sequencing capabilities in the early stages of their partnership. In the most recent phase, the parties created a nationwide platform for gathering and archiving de-identified consenting specimens from subjects taking part in studies supported by pharmacological, academic, and patient engagement groups. Quest’s 2,100 patient care locations, ExamOne’s mobile in-home phlebotomy team, and a biobank at its sophisticated laboratory in Memphis, Tennessee, are all included in the platform. The partnership is important because biomarker-based information may speed up and lower the cost of creating revolutionary diagnostic tests and finding new medication targets. In about 60% of clinical studies, methods for identifying therapy biomarkers are used. As part of the partnership, Quest and Decode will split any profits from new research, data licencing, the discovery of biomarkers, or the creation of diagnostics. “Opportunities to significantly improve healthcare are hidden within data, especially for diagnostic and drug discoveries,” says Chase Spurlock, PhD, co-founder and CEO of Decode Health. “The work we are doing today with Quest Diagnostics aims to unlock those discoveries. Every day, we build upon our collective goal to advance precision medicine and improve health outcomes across a growing number of conditions. By collaborating with key healthcare stakeholders, including pharma, we believe that our work will create opportunities to fuel critical advances that unlock the next generation of cutting-edge diagnostics and therapeutics.”

Decode Health gets results quickly, which speeds up the time to value and gives its partners a competitive edge from implementation to insight.